In particular, the NUTM1-rearranged (NUTM1-immunopositive) cases should be distinguished from the more aggressive NUT carcinoma, as both share overlapping anatomic sites and squamous cell phenotype and express NUTM1. This evidence concerns the gene NUTM1 and nut midline carcinoma.